Vaxcyte Inc (PCVX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Vaxcyte Inc stock $47.33, price $61.61, that is 23.2% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Show moreShow less
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Stock analysis
Vaxcyte Inc (PCVX) currently trades at $61.61, while our estimate is $47.33, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $35.49 (bear) to $59.16 (bull), the price of $61.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Vaxcyte Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$767M in FY2025.
Key figures
Market cap $9.8B Mid · EPS (TTM) $−8.05 · Return on equity −36.5% · Return on assets (EBIT) −27.0% (5-year average) · Free cash flow −$669M · Net debt $54.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, PCVX screens richer than that median.
Fair Value
Bear$35.49Fair Value $47.33Bull$59.16
Price $61.61 · Downside -23.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality26/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth25
Are margins and returns getting better?
Cashflow24
Do the profits arrive as real cash?
Financial strength80
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility27
How calm the share price moves, does not count
Price momentum67
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 5 officers or directors sold shares worth $11.8M and none bought.
SaleHarpreet S. DhaliwalChief Technical Ops Officer3× since Dec 31, 2025: 43,743 shares, avg. $58.14$2.5MNov 11, 2026
SaleJim WassilEVP, Chief Scientific Ofc, COO11× since Mar 10, 2026: 47,337 shares, avg. $68.79$3.3MNov 2, 202610b5-1 plan
SaleElvia CowanSVP, Finance & CAO6× since Dec 23, 2025: 41,015 shares, avg. $68.74$2.8MNov 2, 2026
SaleAndrew GuggenhimePRESIDENT AND CFO3× since Jun 18, 2026: 30,000 shares, avg. $54.72$1.6MAug 3, 202610b5-1 plan
SaleGrant PickeringCHIEF EXECUTIVE OFFICER, Director3× since Jun 18, 2026: 66,896 shares, avg. $54.34$3.6MJul 27, 202610b5-1 plan
Plus 33 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
News mood ⓘNews mood, the average tone of recent news (89 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Vaxcyte demonstrates a narrow moat via its cell-free platform's Phase 3 success, yet its core weakness remains the pre-commercial stage with pending trial outcomes and manufacturing scale-up.
Main risk: Pfizer's Prevnar and Merck's Capvaxive could retain significant market share or offer competitive advantages, limiting Vaxcyte's ability to gain customers or achieve desired pricing and margins for its PCV candidates.
Bull case: Successful Phase 3 data and regulatory approval could allow Vaxcyte to capture market share from established rivals with its broader-coverage vaccine.
Bear case: Failure to secure manufacturing scale-up or FDA approval due to platform novelty could leave the company without commercial products and reliant on further financing.
Vaxcyte's cell-free platform produced positive Phase 3 results for its 31-valent pneumococcal candidate in adults, meeting all primary endpoints with a safety profile comparable to existing vaccines. The remaining adult trials and infant data due in 2027 plus manufacturing scale-up still lie ahead before any potential 2028 launch. Will those next readouts deliver the same level of differentiation or reveal limits in real-world performance?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside−23.2% · Above median
Profitability
Return on assets−25.2% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vaxcyte Inc Fair Value". https://www.fairvalue-calculator.com/stock/PCVX
Frequently asked questions
Is Vaxcyte Inc (PCVX) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $47.33 versus a price of $61.61, about 23% lower (overvalued).
What is the fair value of PCVX?
Our estimate for Vaxcyte Inc is $47.33 (as of Nov 16, 2026), built from audited fundamentals. The current price: $61.61.
What is the quality score of PCVX?
Vaxcyte Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vaxcyte Inc (PCVX)?
Our calculated price target is the estimate of $47.33 (as of Nov 16, 2026). Cautious scenario $35.49, optimistic scenario $59.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vaxcyte Inc stock forecast for 2026?
Our estimate puts fair value at $47.33, about 23% lower versus a price of $61.61 (overvalued). Cautious scenario $35.49, optimistic scenario $59.16. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Vaxcyte Inc (PCVX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaxcyte Inc it is $47.33 per share (as of Nov 16, 2026), against a price of $61.61.
Is Vaxcyte Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, PCVX trades above its calculated fair value: price $61.61, fair value $47.33, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCVX?
No. The price is what the market pays today ($61.61); the fair value is what the company's own numbers justify ($47.33). For Vaxcyte Inc the two are $14.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vaxcyte Inc worth?
The market values Vaxcyte Inc at about $9.8B (market capitalisation, as of Nov 16, 2026). Per share that is $61.61; our models calculate a fair value of $47.33 per share.
What do the bullish and bearish scenarios say about PCVX?
Our models span a range for Vaxcyte Inc: cautious scenario $35.49, base $47.33, optimistic $59.16 per share (as of Nov 16, 2026, price $61.61). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vaxcyte Inc (PCVX)?
Balance-sheet figures for Vaxcyte Inc (as of Nov 16, 2026): return on equity −36.5%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is PCVX from its 52-week high?
Vaxcyte Inc trades at $61.61, about 17% below its 52-week high of $73.82 and 43% above the low of $43.06 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $47.33 is for.
Which stocks are comparable to Vaxcyte Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vaxcyte Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $61.61, calculated fair value $47.33 (−23%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Vaxcyte Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vaxcyte Inc (PCVX)?
The closing price on Nov 16, 2026 was $61.61. Our estimate is $47.33, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vaxcyte Inc right now?
The price sits above even our optimistic bull case ($59.16). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Vaxcyte Inc
How large is the market capitalisation of Vaxcyte Inc (PCVX)?
The market capitalisation of Vaxcyte Inc is $9.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Vaxcyte Inc (PCVX)?
Earnings per share at Vaxcyte Inc are $−8.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Vaxcyte Inc (PCVX)?
The return on equity (ROE) of Vaxcyte Inc is −36.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vaxcyte Inc (PCVX)?
On an EBIT basis the return on assets of Vaxcyte Inc is −27.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Vaxcyte Inc (PCVX) generate?
The free cash flow of Vaxcyte Inc is −$669M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vaxcyte Inc (PCVX) carry?
The net debt of Vaxcyte Inc is $54.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vaxcyte Inc in the live analysis
One click puts Vaxcyte Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.